Michael Kinch

Q: What Schools Are Affiliated With Michael Kinch

Michael Kinch is affiliated with the following schools: Washington University in St. Louis, Yale University, Purdue University, University of North Carolina at Chapel Hill, University of Auckland, University of Texas Southwestern Medical Center, Duke University, Harvard University

Michael Kinch's AcademicInfluence.com Rankings

Michael Kinch

Law

#2888

World Rank

#3601

Historical Rank

#1230

USA Rank

Common Law

#167

World Rank

#180

Historical Rank

#25

USA Rank

law Degrees

Download Badge

Michael Kinch's Degrees

Doctorate Medicine Harvard University

Why Is Michael Kinch Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Michael Scott Kinch is an American academic and author of books on the history of science and medicine. He has helped lead innovation and entrepreneurship activities at Washington University in St Louis since 2014.

(See a Problem?)

Michael Kinch's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation (1995) (714)
Integrin-mediated cell adhesion activates mitogen-activated protein kinases. (1994) (682)
Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation (2000) (556)
An analysis of FDA-approved drugs: natural products and their derivatives. (2016) (507)
An analysis of FDA-approved drugs: natural products and their derivatives. (2016) (507)
EphA2 overexpression causes tumorigenesis of mammary epithelial cells. (2001) (461)
Divergent C-H functionalizations directed by sulfonamide pharmacophores: late-stage diversification as a tool for drug discovery. (2011) (346)
Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia (1995) (320)
E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. (1999) (263)
Overexpression of the EphA2 tyrosine kinase in prostate cancer (1999) (263)
Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). (2001) (260)
Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. (2003) (234)
EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma (2004) (212)
Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. (2002) (203)
An overview of FDA-approved new molecular entities: 1827-2013. (2014) (185)
An overview of FDA-approved new molecular entities: 1827-2013. (2014) (185)
The Ras-related Protein Rheb Is Farnesylated and Antagonizes Ras Signaling and Transformation* (1997) (184)
Rho-stimulated contractility contributes to the fibroblastic phenotype of Ras-transformed epithelial cells. (1997) (178)
Dynamic Interaction of PTPμ with Multiple Cadherins In Vivo (1998) (175)
VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: Implications for vasculogenic mimicry (2006) (165)
Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. (2003) (150)
Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade (2002) (149)
c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. (2002) (149)
Regulation of the EphA2 Kinase by the Low Molecular Weight Tyrosine Phosphatase Induces Transformation* (2002) (149)
Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer (2004) (146)
EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. (2005) (144)
An overview of FDA-approved biologics medicines. (2015) (143)
Differential regulation of EphA2 in normal and malignant cells. (2003) (133)
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. (2006) (127)
Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1 (2004) (123)
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. (2008) (117)
TEL, a Putative Tumor Suppressor, Modulates Cell Growth and Cell Morphology of Ras-Transformed Cells While Repressing the Transcription of stromelysin-1 (2000) (113)
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. (2003) (112)
Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer (2008) (112)
EphA2 overexpression is associated with angiogenesis in ovarian cancer (2007) (110)
Identification of Small Molecule Inhibitors of Jumonji AT-rich Interactive Domain 1B (JARID1B) Histone Demethylase by a Sensitive High Throughput Screen* (2013) (105)
Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder (2006) (104)
EphA2 as a target for ovarian cancer therapy (2005) (104)
Differential EphA2 epitope display on normal versus malignant cells. (2003) (103)
A new strategy for selective protein cleavage (1990) (99)
The human antiporcine cellular repertoire. In vitro studies of acquired and innate cellular responsiveness. (1993) (98)
Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. (2005) (98)
An analysis of FDA-approved drugs for infectious disease: antibacterial agents. (2014) (96)
An analysis of FDA-approved drugs for infectious disease: antibacterial agents. (2014) (96)
An analysis of FDA-approved drugs for infectious disease: antibacterial agents. (2014) (96)
E-Cadherin Binding Modulates EGF Receptor Activation (2003) (96)
Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. (1996) (91)
Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists. (1995) (89)
Development of a broad-spectrum antiviral with activity against Ebola virus. (2009) (86)
Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. (2012) (85)
Predicting the sites of metastases from lung cancer using molecular biologic markers. (2001) (84)
Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™ (2006) (84)
Potent inhibitors of LpxC for the treatment of Gram-negative infections. (2012) (84)
Loss of 14-3-3σ in Prostate Cancer and Its Precursors (2004) (81)
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. (2007) (80)
EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. (2003) (77)
PC Cell-Derived Growth Factor Expression in Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma (2004) (77)
The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza. (2009) (76)
Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection (2010) (72)
Integrating intramolecular hydrogen bonding (IMHB) considerations in drug discovery using ΔlogP as a tool. (2013) (70)
Sequential allylic C-H amination/vinylic C-H arylation: a strategy for unnatural amino acid synthesis from α-olefins. (2012) (65)
MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. (2001) (65)
Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. (2008) (65)
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance (2016) (61)
An analysis of FDA-approved drugs for oncology. (2014) (61)
EphA2 overexpression promotes ovarian cancer growth (2008) (59)
The fluorine atom as a cation-stabilizing auxiliary in biomimetic polyene cyclizations. IV: Total synthesis of dl-β-amyrin (1993) (59)
Asymmetric tandem addition to chiral 1- and 2-substituted naphthalenes. Application to the synthesis of (+)-phyltetralin (1988) (59)
Diversification of a β-Lactam Pharmacophore via Allylic C-H Amination: Accelerating Effect of Lewis Acid Co-Catalyst. (2010) (58)
Novel Riboswitch-Binding Flavin Analog That Protects Mice against Clostridium difficile Infection without Inhibiting Cecal Flora (2015) (56)
Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase (2002) (55)
Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging. (2016) (54)
FGI-104: a broad-spectrum small molecule inhibitor of viral infection. (2009) (54)
An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs. (2014) (53)
Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma (2017) (53)
Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma (2017) (53)
Loss of 14-3-3sigma in prostate cancer and its precursors. (2004) (52)
E-cadherin engagement stimulates tyrosine phosphorylation. (1997) (50)
Pyridone-conjugated monobactam antibiotics with gram-negative activity. (2013) (49)
Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. (2006) (47)
4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase. (2007) (43)
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists. (1997) (41)
Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer (2011) (39)
Structure guided development of novel thymidine mimetics targeting Pseudomonas aeruginosa thymidylate kinase: from hit to lead generation. (2012) (38)
Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand. (1997) (37)
EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells. (2004) (37)
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. (2009) (36)
An analysis of original research contributions toward FDA-approved drugs. (2015) (35)
An analysis of original research contributions toward FDA-approved drugs. (2015) (35)
TEL, a Putative Tumor Suppressor, Induces Apoptosis and Represses Transcription of Bcl-XL* (2003) (34)
Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents. (2012) (33)
The Role of 4-phosphonodifluoromethyl- and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands (1997) (32)
EphA 2 Overexpression Causes Tumorigenesis of Mammary Epithelial Cells 1 (2001) (32)
Cell adhesion mediated by CD4 and MHC class II proteins requires active cellular processes. (1993) (32)
Molecular Basis of Purinergic Signal Metabolism by Ectonucleotide Pyrophosphatase/Phosphodiesterases 4 and 1 and Implications in Stroke*♦ (2013) (31)
The engagement of β1 integrins on promonocytic cells promotes phosphorylation of Syk and formation of a protein complex containing Lyn and β1 integrin (1999) (31)
2,5-Cyclohexadien-1-one to bicyclo[3.1.0]hexenone photorearrangement. Development of the reaction for use in organic synthesis (1987) (29)
Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists1 (2008) (27)
Intramolecular cycloadditions to oxyallyl zwitterions generated from photorearrangements of 2,5-cyclohexadien-1-ones (1988) (27)
Identification of tyrosine phosphorylated adhesion proteins in human cancer cells. (1998) (26)
Trends in pharmaceutical targeting of clinical indications: 1930-2013. (2014) (26)
The rise (and decline?) of biotechnology. (2014) (26)
2017 in review: FDA approvals of new molecular entities. (2018) (26)
Food and microbiota in the FDA regulatory framework (2017) (25)
Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway. (2003) (25)
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma (2006) (25)
A mechanism for trabecular meshwork cell retraction: ethacrynic acid initiates the dephosphorylation of focal adhesion proteins. (1997) (24)
Design and synthesis of renin inhibitors: incorporation of transition-state isostere side chains that span from the S1 to the S3 binding pockets and examination of P3-modified renin inhibitors. (1995) (24)
Target selection for FDA-approved medicines. (2015) (24)
Target selection for FDA-approved medicines. (2015) (24)
Workgroup 2: Human xenograft models of prostate cancer (1998) (24)
Altered adhesions in ras-transformed breast epithelial cells. (1995) (24)
Target selection for FDA-approved medicines. (2015) (24)
2016 in review: FDA approvals of new molecular entities. (2017) (23)
Asymmetric tandem additions to chiral 2-naphthyloxazolines. The synthesis of enantiomerically pure 1,2,2-trisubstituted- 1,2-dihydronaphthalenes (1984) (22)
Intramolecular 2 + 2 photocycloadditions of 4-(3'-alkenyl)- and 4-(3'-pentynyl)-2,5-cyclohexadien-1-ones (1988) (22)
An annulation approach to the synthesis of pseudoguaianolide sesquiterpene lactones. Total syntheses of dl-confertin and dl-aromatin (1986) (21)
Expression of EphA 2 and Ephrin A-1 in Carcinoma of the Urinary Bladder (2006) (21)
An analysis of FDA-approved drugs for neurological disorders. (2015) (21)
Novel phosphotyrosine mimetics in the design of peptide ligands for pp60src SH2 domain (1996) (21)
Design of peptidomimetic ligands for the pp60src SH2 domain. (1997) (21)
Small molecule fluoride toxicity agonists. (2015) (20)
Stereochemistry of the Ph3P-CCl4 mediated cyclization of carboxylic acids and 1,2-amino alcohols (Vorbruggen method) (1985) (20)
Structure-based design of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1). (2002) (19)
YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors (2015) (19)
An overview of FDA-approved vaccines & their innovators (2017) (18)
Biomimetic polyene cyclizations. Cationic cyclization of a substrate having an internal acetylenic bond. Synthesis of euphol and tirucallol (1990) (18)
Structure-based design of caspase-1 inhibitor containing a diphenyl ether sulfonamide. (2001) (17)
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections. (2012) (17)
Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors. (2013) (17)
CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11. (2002) (16)
Dual Genetic Encoding of Acetyl-lysine and Non-deacetylatable Thioacetyl-lysine Mediated by Flexizyme. (2016) (16)
An analysis of FDA-approved drugs for inflammation and autoimmune diseases. (2015) (15)
Hydrophobic D-amino acids in the design of peptide ligands for the pp60src SH2 domain. (1996) (15)
The protein tyrosine kinase p56lck regulates cell adhesion mediated by CD4 and major histocompatibility complex class II proteins (1994) (14)
Interactions of CD4 with MHC class II molecules, T cell receptors and p56lck. (1993) (14)
Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy. (2013) (13)
The engagement of beta1 integrins on promonocytic cells promotes phosphorylation of Syk and formation of a protein complex containing Lyn and beta1 integrin. (1999) (13)
A γ-Lactam Siderophore Antibiotic Effective Against Multidrug-Resistant Gram-Negative Bacilli. (2020) (13)
A γ-Lactam Siderophore Antibiotic Effective Against Multidrug-Resistant Gram-Negative Bacilli. (2020) (13)
The antimalarial activity of the pantothenamide α-PanAm is via inhibition of pantothenate phosphorylation (2017) (12)
Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry. (2016) (12)
2015 in review: FDA approval of new drugs. (2016) (12)
α-((Tetronoyl)oxy)- and α-((tetramoyl)oxy)methyl ketone inhibitors of the interleukin-1β converting enzyme (ICE) (1997) (12)
Peptidomimetic inhibitors of renin incorporating topographically modified isosteres spanning the P1(→ P3)-P1' sites (1993) (12)
High-throughput screening identifies compounds that protect RPE cells from physiological stressors present in AMD. (2019) (11)
The efficient synthesis of (3R,4R,5R)-3-amino-4,5-dimethyl-octanoic acid, a chiral β-amino acid with potent affinity for the α2δ protein (2009) (11)
Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases. (2019) (10)
A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. (2021) (9)
2018 in review: FDA approvals of new molecular entities. (2019) (9)
New drug discovery: extraordinary opportunities in an uncertain time. (2015) (9)
A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. (2021) (9)
CDEK: Clinical Drug Experience Knowledgebase (2018) (9)
Analysis of FDA-approved imaging agents. (2017) (9)
An analysis of FDA-approved drugs for cardiovascular diseases. (2016) (9)
Development and optimization of a high-throughput screening method utilizing Ancylostoma ceylanicum egg hatching to identify novel anthelmintics (2019) (9)
An analysis of FDA-approved drugs for cardiovascular diseases. (2016) (9)
Structure activity relationships of non-peptide bradykinin B2 receptor antagonists (1995) (8)
TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. (2010) (7)
MCF-10 A-NeoST : A New Cell System for Studying Cell-ECM and Cell-Cell Interactions in Breast Cancer 1 (2001) (7)
976. Decreased Tumorigenic Potential of EphA2-Overexpressing Breast Cancer Cells Following Treatment with Adenoviral Vectors That Express EphrinA1 (2004) (7)
Antibody Targeting of the EphA 2 Tyrosine Kinase Inhibits Malignant Cell Behavior 1 (2002) (7)
An analysis of FDA-approved drugs for pain and anesthesia. (2015) (7)
An analysis of FDA-approved drugs for psychiatric disorders. (2015) (6)
Sources of innovation for new medicines: questions of sustainability. (2020) (6)
Identification of annexin A13 as a regulator of chemotherapy resistance using random homozygous gene perturbation. (2010) (6)
Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats. (2002) (6)
CHRONIC ORAL TOXICITY (2008) (6)
Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery. (2019) (6)
Development of FGI-106 as a broad-spectrum therapeutic with activity against members of the family Bunyaviridae (2010) (5)
Antivascular Effects of EphA 2 Reduction With an Agonistic Antibody in Ovarian Cancer (2006) (5)
Identification of novel host-oriented targets for Human Immunodeficiency Virus type 1 using Random Homozygous Gene Perturbation (2009) (5)
Analysis of cell migration. (2001) (5)
Identification of PTCH1 requirement for influenza virus using random homozygous gene perturbation. (2009) (5)
2014 in review: FDA approval of new drugs. (2017) (5)
Sources of innovation: an assessment of intellectual property. (2015) (5)
An analysis of FDA-approved drugs for metabolic diseases. (2015) (5)
An analysis of FDA-approved drugs for metabolic diseases. (2015) (5)
Rabbit milk Ruconest for hereditary angioedema (2014) (5)
Expression and purification of the intact cytoplasmic domain of the human ephrin receptor A2 tyrosine kinase in Escherichia coli. (2006) (5)
Expanding roles for academic entrepreneurship in drug discovery (2020) (5)
Pyrrolocin A, a 3-Decalinoyltetramic Acid with Selective Biological Activity, Isolated from Amazonian Cultures of the Novel Endophyte Diaporthales sp. E6927E (2015) (4)
Pyrrolocin A, a 3-Decalinoyltetramic Acid with Selective Biological Activity, Isolated from Amazonian Cultures of the Novel Endophyte Diaporthales sp. E6927E (2015) (4)
2021 in review: FDA approvals of new medicines. (2022) (4)
One-pot (1-ethoxycarbonylcyclopropyl)triphenylphosphonium tetrafluoroborate ring-opening and Wittig reaction. (2011) (4)
Cation-Stabilizing Auxiliaries in Polyene Cyclizations. Part 7. The Fluorine Atom as a Cation-Stabilizing Auxiliary in Biomimetic Polyene Cyclizations. Part 4. Total Synthesis of dl-β-Amyrin. (1993) (4)
Palladium-catalyzed cross-coupling in the synthesis of pyridinyl boxazomycin C analogues. (2005) (4)
Peptidomimetic Ligands for Src Homology-2 Domains (1999) (4)
A history of drug development in four acts. (2015) (3)
Structure-based design of novel, dipeptide ligands targeting the pp60Src SH2 domain (1997) (3)
Antibody targeting of TSG101 on influenza-infected cells (2010) (3)
Phosphorylated WNK kinase networks in recoded bacteria recapitulate physiological function (2021) (3)
Borate promoted electrophilic additions of alkyl hypohalites (1982) (3)
Enhancement in Specific CD 8 T Cell Recognition of EphA 2 Tumors In Vitro and In Vivo after Treatment with Ligand Agonists 1 (2008) (3)
Function-first approaches to improve target identification in cancer. (2009) (3)
A Prescription for Change (2016) (3)
A history of drug development in four acts. (2015) (3)
2020 in review: FDA approvals of new medicines. (2021) (3)
A Prescription for Change: The Looming Crisis in Drug Development (2016) (2)
Post-approval fate of pharmaceutical companies. (2015) (2)
4484 The Entrepreneurship for Biomedicine (E4B) Training Program (2020) (2)
A Novel Innovation and Entrepreneurship (I&E) Training Program for Biomedical Research Trainees. (2022) (2)
Virus Adaptation and Treatment (2010) (2)
High-resolution crystal structure and chemical screening reveal pantothenate kinase as a new target for antifungal development. (2022) (2)
Recruitment of the TSG101/ESCRT-I Machinery in Host Cells by Influenza Virus: Implications for Broad-Spectrum Therapy (2009) (2)
NIH Support for FDA-Approved Medicines. (2017) (2)
2019 in review: FDA approvals of new medicines. (2020) (2)
A reconsideration of university gap funds for promoting biomedical entrepreneurship (2022) (1)
Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma? (2020) (1)
Structure-based de novo design and discovery of nonpeptide antagonists of the pp60src (Src) SH2 domain (2002) (1)
Design and Synthesis of Renin Inhibitors: Incorporation of Transition‐ State Isostere Side Chains That Span from the S1 to the S3 Binding Pockets and Examination of P3‐Modified Renin Inhibitors. (1995) (1)
Sources of Biopharmaceutical Innovation: An Assessment of Intellectual Property (2015) (1)
Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore (2021) (1)
Oh, the Frustration of Antibodies! (2020) (1)
Novel Phosphotyrosine Mimetics in the Design of Peptide Ligands for pp60src SH2 Domain. (2010) (1)
Mechanistic Evaluation of Siplizumab (MEDI-507) Activity on Normal and Malignant T-Lymphocytes. (2006) (1)
Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore (2021) (1)
Monoclonal antibodies: trends in therapeutic success and commercial focus. (2022) (1)
EA5, novel EphA2-targeted monoclonal antibody, inhibits growth and metastasis in human breast cancer xenografts (2005) (1)
Confronting the COVID ‐19 Pandemic: December 2019–May 2020 (2021) (0)
2,5-Cyclohexadien-1-one to Bicyclo(3.1.0)hexenone Photorearrangement. Development of the Reaction for Use in Organic Synthesis. (1987) (0)
Pyridazines as interleukin-1-beta transformation enzyme inhibitors (1994) (0)
FDA‐Approved Medicines (2021) (0)
687. In vitro Activity of a New Generation Oxopyrazole Antibiotic Against Acinetobacter spp. (2019) (0)
ACE Inhibitors as a Template for the Disign of Bradykinin B2 Receptor Antagonists. (1995) (0)
Pyrimidopyrimidone as kinase inhibitors (2003) (0)
698. In vitro Activity of a New Generation Oxopyrazole Antibiotic Against Multidrug-Resistant Gram-Negative Bacilli (2019) (0)
Alfa-heteroaryylioksimetyyliketoneja as inhibitors of interleukin-converting enzyme 1betaa (1994) (0)
Stereochemistry of the Ph3P-CCl4Mediated Cyclization of Carboxylic Acids and 1,2-Amino Alcohols (Vorbruggen Method). (1986) (0)
Targeting Pantothenate Kinase as an Effective Strategy for Antifungal Drug Development (2022) (0)
Differential Substrate Profile of the EphA2 Tyrosine Kinase in Non-Transformed and Malignant Breast Epithelia (2002) (0)
Benzo (b) thiophenes substituted 3-aryloxy and 3-heteroaryloxy as therapeutic agents with PI3K activity. (2004) (0)
Patents, trade secrets and pricing. (2022) (0)
Biopharmaceutical agents - Active drugs of the future (2009) (0)
ASYMMETRIC TANDEM ADDITIONS TO CHIRAL 2-NAPHTHYLOXAZOLINES. THE SYNTHESIS OF ENANTIOMERICALLY PURE 1,2,2-TRISUBSTITUTED 1,2-DIHYDRONAPHTHALENES (1985) (0)
Agents antibacteriens a la quinolone (2004) (0)
Asymmetric Tandem Addition to Chiral 1- and 2-Substituted Naphthalenes. Application to the Synthesis of (+)-Phyltetralin. (1988) (0)
Peptide analogues with irreversible interleukin-1 beta protease inhibitors (1994) (0)
Antibody-DependentCell-MediatedCytotoxicityEffector – Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors 1 (2009) (0)
Participation, Survey, and Start-Up License Agreement Data from the LEAP Program at Washington University in St. Louis (2022) (0)
4328 Translational Fellows as a mechanism to improve throughput of university technology commercialization (2020) (0)
FG01 human gene and its applications (2009) (0)
Structure Activity Relationships of Non-Peptide Bradykinin B2 Receptor Antagonists. (1995) (0)
Accelerating Effect of Lewis Acid Co-Catalyst on C-H Amination (2010) (0)
A process for the production of test elements (1993) (0)
Identification of a Small-molecule Antiviral with Broad-spectrum Application to Multiple, Lethal Virus Types (2009) (0)
3-aryloxy-and 2-substituted heteroaryloxy-benzo [b] thiophene as a therapeutic agent with PI3K activity (2004) (0)
Corrigendum to “Novel monobactams utilizing a siderophore uptake mechanism for the treatment of Gram-negative infections” [Bioorg. Med. Chem. Lett. 22/18 (2012) 5989–5994] (2015) (0)
Intramolecular Cycloadditions of Alkenes to Oxyallyl Zwitterions Generated from Photorearrangements of 2,5-Cyclohexadien-1-ones. (1988) (0)
Pyridazines as inhibitors of the enzyme conversion of interleukin-1beta the. (1994) (0)
Chapter 28 Cytometric analysis of cell contact and adhesion (2001) (0)
687. In vitro Activity of a New Generation Oxopyrazole Antibiotic Against Acinetobacter spp. (2019) (0)
[Dual genetic encoding of acetyl-lysine and non-deacetylatablethioacetyl-lysine mediated by flexizyme]. (2016) (0)
Topographically designed peptidomimetic inhibitors of human renin: Incorporation of novel, tethered P1 → P3 side chain functionalization (1994) (0)
Interleukin-1 beta conversion enzyme inhibitor (1994) (0)
YU 238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-De fi cient Tumors (2015) (0)
An Annulation Approach to the Synthesis of Pseudoguaianolide Sesquiterpene Lactones. (1986) (0)
Between Hope and Fear (2018) (0)
EphA2 antibodies directed against a cancer diagnosis. (2000) (0)
00002 Translational Fellows as a mechanism to improve throughput of university technology commercialization (2021) (0)
Intramolecular 2 + 2 Photocycloadditions of 4-(3′-Alkenyl)- and 4-(3′-Pentynyl)-2,5-cyclohexadien-1-ones. (1988) (0)
Pirimidopirimidonas as kinase inhibitors. (2003) (0)
Characterization of an Adhesion-Associated Tumor Suppressor in Breast Cancer (1999) (0)
Pyridazine as interleukin-1 beta-converting enzyme inhibitors reshaped (1994) (0)
Protein composition with biological activity (1993) (0)
Cytometric analysis of cell contact and adhesion. (2001) (0)
Pyridazines as inhibitors of interleukin-converting enzyme 1betaa (1994) (0)
Sequential Allylic C—H Amination/Vinylic C—H Arylation: A Strategy for Unnatural Amino Acid Synthesis from α‐Olefins. (2012) (0)
698. In vitro Activity of a New Generation Oxopyrazole Antibiotic Against Multidrug-Resistant Gram-Negative Bacilli (2019) (0)
Anticorps utilises dans le diagnostic du cancer (2000) (0)
1256. In Vivo Activity and Structural Characterization of a New Generation γ-Lactam Siderophore Antibiotic Against Multidrug-Resistant Gram-Negative Bacteria and Acinetobacter spp (2020) (0)
Organs-on-chips Harvard spinout (2014) (0)
The antimalarial activity of the pantothenamide α-PanAm is via inhibition of pantothenate phosphorylation (2017) (0)
Immunoconjugates and bispecific antibodies: trends in therapeutic success and commercial focus. (2022) (0)

This paper list is powered by the following services:

Other Resources About Michael Kinch

en.wikipedia.org

What Schools Are Affiliated With Michael Kinch?

Michael Kinch is affiliated with the following schools:

Michael Kinch's Academic­Influence.com Rankings